A5088122908- Venous Thromboembolism Diagnosis and Management
- Blood Coagulation and Thrombosis Mechanisms
- Atrial Fibrillation Management and Outcomes
- Hemophilia Treatment and Research
- Central Venous Catheters and Hemodialysis
- Diagnosis and Treatment of Venous Diseases
- Cardiac Arrhythmias and Treatments
- Blood properties and coagulation
- Antiplatelet Therapy and Cardiovascular Diseases
- Heparin-Induced Thrombocytopenia and Thrombosis
- Liver Disease and Transplantation
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Systemic Lupus Erythematosus Research
- Liver Disease Diagnosis and Treatment
- Platelet Disorders and Treatments
- Cardiovascular Issues in Pregnancy
- Acute Ischemic Stroke Management
- Organ Transplantation Techniques and Outcomes
- Acute Myocardial Infarction Research
- Cardiac electrophysiology and arrhythmias
- Pregnancy and preeclampsia studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Peripheral Artery Disease Management
- Folate and B Vitamins Research
- Blood Pressure and Hypertension Studies
Weatherford College
1997-2024
University of Bologna
2010-2024
Azienda USL di Bologna
2024
Istituti di Ricovero e Cura a Carattere Scientifico
2024
Policlinico S.Orsola-Malpighi
2010-2022
Ospedale Maggiore
2010
University of Milan
2001-2010
University of the Republic of San Marino
2009
Universidad de la República de Uruguay
2007-2008
Hospital de Clínicas
2007-2008
D-dimer assay, generally evaluated according to cutoff points calibrated for VTE exclusion, is used estimate the individual risk of recurrence after a first idiopathic event venous thromboembolism (VTE).Commercial assays, predetermined levels each specific age (lower in subjects <70 years) and gender males), were recent DULCIS study. The present analysis compared results obtained with those that might have been had using following different criteria: traditional higher aged ≥60 years, or...
The optimal duration of oral anticoagulation in patients with idiopathic venous thromboembolism is uncertain. Testing D-dimer levels may play a role the assessment need for prolonged anticoagulation.We performed testing 1 month after discontinuation first unprovoked proximal deep-vein thrombosis or pulmonary embolism who had received vitamin K antagonist at least 3 months. Patients normal level did not resume anticoagulation, whereas those an abnormal were randomly assigned either to...
Summary In some patients with previous venous thromboembolism (VTE) D-dimer levels (D-Dimer) tend to increase after oral anticoagulant therapy (OAT) is stopped. The aim of our study was evaluate the predictive value D-Dimer for risk VTE recurrence OAT withdrawal. After a first episode deep vein thrombosis (DVT) lower limbs and/or pulmonary embolism (PE), 396 (median age 67 years, 198 males) were followed from day discontinuation 21 months. measured on withdrawal (T1), 3-4 weeks (T2) and 3...
Background— We have shown that normal D-dimer levels obtained after the discontinuation of oral anticoagulant treatment (OAT) has a high negative predictive value for recurrent venous thromboembolism (VTE). The aim present study was to assess VTE in subjects with previous unprovoked event who are either carriers inherited thrombophilia or not. Methods and Results— prospectively evaluated 599 patients (301 males) episode. They were repeatedly examined OAT withdrawal screened thrombophilic...
The optimal long-term treatment of acute venous thromboembolism (VTE) in patients with malignancy remains undefined. In particular, based on current evidence, it is uncertain whether secondary prophylaxis using standard intensity oral anticoagulant therapy associated higher risks bleeding and recurrent thrombosis cancer than those without cancer. This study compared the outcome anticoagulation courses 95 733 malignancy. All were participants a large, nation-wide population prospectively...
Unlabelled Box<li>•Direct oral anticoagulants (DOACs) do not require laboratory monitoring currently.</li><li>•DOAC specific measurements were performed at trough in patients with atrial fibrillation.</li><li>•Patients who developed thromboembolic events showed lower DOAC plasma levels.</li><li>•This study supports the concept of measuring levels steady state.</li>The Arianna Anticoagulation Foundation supported START Register and study. The had no role design, collection, analysis...
Background D-dimer testing to rule out deep vein thrombosis is less useful in older patients because of a lower specificity. An age-adjusted cut-off value increased the proportion (>50 years) whom pulmonary embolism could be excluded. We retrospectively validated efficacy this combined with clinical probability for exclusion thrombosis.Design and Methods Five management study cohorts 2818 consecutive outpatients suspected were used. Patients non-high or unlikely included analysis; four...
Unlabelled Box<li>•Currently, DOACs are given at fixed doses and do not require laboratory monitoring.</li><li>•Direct oral anticoagulant‐specific measurements were performed trough peak.</li><li>•Patients who developed bleeding events showed higher DOAC plasma levels peak.</li><li>•This study suggests the need of a more accurate dose assessment.</li> <h3>Background</h3> Direct anticoagulants (DOACs) administered dose. The aim was to evaluate relationship between C‐trough or C‐peak...
Although effective and safe, treatment with direct oral anticoagulants (DOAC) in atrial fibrillation (AF) is still associated thrombotic complications. Whether the measurement of DOAC levels may improve efficacy an open issue. We carried out observational, prospective, multicenter Measure See (MAS) study. Blood was collected 15 to 30 days after starting patients AF who were followed-up for 1 year. Plasma samples centralized level measurement. Patients' converted into drug/dosage standardized...
Abstract A genetic variation in the 3′-untranslated region of prothrombin mRNA (20210 G/A) has recently been reported to be associated with elevated plasma levels and an increased incidence venous thrombosis. We determined frequency this mutation, detection which was improved by allele-specific amplification exon 14 denaturing gradients (denaturing gradient gel electrophoresis), cohorts patients affected thrombosis (n=132) or coronary cerebrovascular diseases (n=195) normal subjects from...
Summary Oral anticoagulants (OA) are the drug of choice for stroke prevention in patients with non-rheumatic atrial fibrillation (NRAF). This clear benefit/risk ratio comes from several randomized clinical trials (RCT) which highly selected were strictly monitored. The aim this study was to ascertain whether safety OA also obtained outside setting consecutive starting treatment and routinely followed at Italian anticoagulation clinics. A total 433 NRAF enrolled ISCOAT up a mean 1.4 years....
Homozygous carriers of factor V Leiden have an approximately 80-fold increased risk venous thrombosis. Also double heterozygous both the and prothrombin gene mutations are at high thrombotic risk. The magnitude thrombosis in pregnant women with two severe thrombophilic conditions has not been estimated so far. We performed a multicenter retrospective family study homozygous Leiden, mutation, normal coagulation. Only relatives index patients formed cohort. Fifteen 39 were compared to 182...
Summary The natural history of calf deep-vein thrombosis (DVT) is still uncertain and it debated whether warrants to be diagnosed treated. We aimed investigate the complication rate untreated isolated DVT (ICDVT). Symptomatic outpatients were prospectively managed with serial compression ultrasonography (SCUS). Those without proximal likely pre-test clinical probability (PCP) or altered D-dimer received immediate subsequent complete examination deep veins (CCUS) by a different operator....